About this Research Topic
Stroke is a leading cause of mortality and disability worldwide. The role of aspirin in preventing recurrence of stroke is well established; yet, there has been growing evidence that dual antiplatelet therapy (DAPT) may work better than using a single antiplatelet agent. DAPT, the combination of aspirin and one ADP-receptor blocker (clopidogrel, prasugrel, or ticagrelor) has been widely prescribed for secondary stroke prevention. Clopidogrel and aspirin combination therapy is a well-known DAPT regime. However, the challenge lies in the ineffectiveness of clopidogrel in some patients with wide range of resistance prevalence rate in different ethnicities, indicating a huge population-based variation. Ticagrelor and prasugrel as potential alternatives to clopidogrel for DAPT have been tested in many studies in the field of cardiovascular disorders but not similarly for ischemic stroke.
Antiplatelet therapy is usually continued long-term, as stopping treatment can increase the risk of another stroke. However, the decision to continue treatment, especially in patients on DAPT, should be individualized and patient-centered, as there may be situations where stopping treatment is necessary due to side effects or other medical conditions. On the other hand, the recommended dosage and duration of DAPT varies partly based on the particular clinical scenario. Therefore, this research topic aims to spotlight the latest findings about the best DAPT regime, including the patient selection, possible antiplatelet combinations, the dose of antiplatelet, the duration of treatment, and effective measures for reducing the adverse events.
We welcome the submission of any type of manuscript supported by the journal (including Original Research, Meta-Analysis, Review, etc.) about the DAPT for mitigating the risk of ischemic stroke. Potential themes related to this topic include, but are not limited to the following:
● Platelet function guided antiplatelet therapy
● Clopidogrel resistance: mechanisms, genetic factors, prevalence rate
● The role of new antiplatelets in DAPT: ticagrelor, prasugrel
● Short-term versus long-term DAPT
● De-escalating DAPT: the possible effective approaches to reduce adverse hemorrhagic events along with maintaining the benefits of stroke prevention
● Recent clinical trials on new and different DAPT regimes
● What we can learn from DAPT in cardiovascular disorders trials
Antiplatelet therapy is usually continued long-term, as stopping treatment can increase the risk of another stroke. However, the decision to continue treatment, especially in patients on DAPT, should be individualized and patient-centered, as there may be situations where stopping treatment is necessary due to side effects or other medical conditions. On the other hand, the recommended dosage and duration of DAPT varies partly based on the particular clinical scenario. Therefore, this research topic aims to spotlight the latest findings about the best DAPT regime, including the patient selection, possible antiplatelet combinations, the dose of antiplatelet, the duration of treatment, and effective measures for reducing the adverse events.
We welcome the submission of any type of manuscript supported by the journal (including Original Research, Meta-Analysis, Review, etc.) about the DAPT for mitigating the risk of ischemic stroke. Potential themes related to this topic include, but are not limited to the following:
● Platelet function guided antiplatelet therapy
● Clopidogrel resistance: mechanisms, genetic factors, prevalence rate
● The role of new antiplatelets in DAPT: ticagrelor, prasugrel
● Short-term versus long-term DAPT
● De-escalating DAPT: the possible effective approaches to reduce adverse hemorrhagic events along with maintaining the benefits of stroke prevention
● Recent clinical trials on new and different DAPT regimes
● What we can learn from DAPT in cardiovascular disorders trials
Keywords: Ischemic Stroke, Antiplatelet, Prevention, aspirin, therapy, clopidogrel, ticagrelor, prasugrel, hemorrhage
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
